SEC Comment Letter for ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510) (VISK) — Oct 12, 2012

ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510)
Date: Oct. 12, 2012 · CIK: 0000727510 · Accession: 0000000000-12-056588

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-12957

Date

December 31, 2011

Author

/s/ Gus Rodriguez

Form

UPLOAD

Company

ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510)

Letter

October 12 , 2012 Via E -mail Mr. George W. Hebard III Interim Principal Executive Officer & Interim Chief Operating Officer Enzon Pharmaceuticals, Inc. 20 Kingsbridge Road Piscataway, NJ 08854

Re: Enzon Pharmaceuticals, Inc. Form 10 -K for the Fiscal Year Ended December 31, 2011 Filed March 12 , 2012 File No. 000-12957

Dear Mr. Hebard :

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission o r any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act o f 1934 and all applicable rules require.

Sincerely,
/s/ Gus Rodriguez

Show Raw Text

October 12 , 2012

Via E -mail
Mr. George W. Hebard III
Interim Principal Executive Officer &
Interim Chief Operating Officer
Enzon Pharmaceuticals, Inc.
20 Kingsbridge Road
Piscataway, NJ 08854

Re:  Enzon Pharmaceuticals, Inc.
 Form 10 -K for the Fiscal Year Ended December  31, 2011
Filed March 12 , 2012
 File No. 000-12957

Dear Mr. Hebard :

We have completed our review of your filing.  We remind you that our comments or
changes to disclosure in response to our comments do not foreclose the Commission from taking
any action with respect to the company or the filing and the company may not assert staff
comments as a defense in any proceeding initiated by the Commission o r any person under the
federal securities laws of the United States.  We urge all persons who are responsible for the
accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the
information the Securities Exchange Act o f 1934 and all applicable rules require.

Sincerely,

        /s/ Gus Rodriguez

Gus Rodriguez
Account ing Branch Chief

SecProbe.io